Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Researchers' work from University of Edinburgh focuses on breast cancer
April 16th, 2009
According to a study from Scotland, "The expression and activation of the Ras/Raf-1/mitogen-activated protein kinase (MAPK) pathway plays an important role in the development and progression of cancer, and may influence response to treatments such as tamoxifen and chemotherapy. In this study we investigated whether the expression and activation of the key components of this pathway influenced clinical outcome, to test the hypothesis that activation of the MAPK pathway drives resistance to tamoxifen and chemotherapy in women with breast cancer." "Breast tumors from patients at the Glasgow Royal Infirmary and others treated within the BR9601 trial were analyzed for...
Source: Women's Health Weekly (2009-04-16)
|
